Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
VolitionRx Limited Appoints Two New Directors
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
VolitionRx Limited to Present at Conferences in March 2021
